Immunovia publ AB (ST:IMMNOV) — Market Cap & Net Worth
Market Cap & Net Worth: Immunovia publ AB (IMMNOV)
Immunovia publ AB (ST:IMMNOV) has a market capitalization of $13.94 Million (Skr129.56 Million) as of June 17, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26228 globally and #552 in its home market, demonstrating a 1.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunovia publ AB's stock price Skr0.19 by its total outstanding shares 672666892 (672.67 Million). Review IMMNOV total debt and obligations to assess the company's total debt and financial obligations.
Immunovia publ AB Market Cap History: 2015 to 2026
Immunovia publ AB's market capitalization history from 2015 to 2026. Data shows change from $2.46 Billion to $13.94 Million (-37.98% CAGR).
Immunovia publ AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunovia publ AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
23.99x
Immunovia publ AB's market cap is 23.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.66 Billion | $177.28K | -$14.72 Million | 37566.01x | N/A |
| 2017 | $6.35 Billion | $148.96K | -$45.23 Million | 42642.78x | N/A |
| 2018 | $9.98 Billion | $332.60K | -$86.54 Million | 29992.34x | N/A |
| 2019 | $13.00 Billion | $356.00K | -$114.52 Million | 36520.20x | N/A |
| 2020 | $8.63 Billion | $362.00K | -$147.45 Million | 23836.61x | N/A |
| 2021 | $5.43 Billion | $844.00K | -$157.40 Million | 6432.73x | N/A |
| 2022 | $1.90 Billion | $1.15 Million | -$145.03 Million | 1662.75x | N/A |
| 2023 | $128.27 Million | $1.57 Million | -$309.44 Million | 81.44x | N/A |
| 2024 | $39.52 Million | $931.00K | -$76.54 Million | 42.45x | N/A |
| 2025 | $16.43 Million | $685.00K | -$145.91 Million | 23.99x | N/A |
Competitor Companies of IMMNOV by Market Capitalization
Companies near Immunovia publ AB in the global market cap rankings as of June 17, 2026.
Key companies related to Immunovia publ AB by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Immunovia publ AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Immunovia publ AB's market cap moved from $2.46 Billion to $ 13.94 Million, with a yearly change of -37.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr13.94 Million | -15.15% |
| 2025 | Skr16.43 Million | -58.42% |
| 2024 | Skr39.52 Million | -69.19% |
| 2023 | Skr128.27 Million | -93.26% |
| 2022 | Skr1.90 Billion | -64.93% |
| 2021 | Skr5.43 Billion | -37.08% |
| 2020 | Skr8.63 Billion | -33.63% |
| 2019 | Skr13.00 Billion | +30.33% |
| 2018 | Skr9.98 Billion | +57.04% |
| 2017 | Skr6.35 Billion | -4.62% |
| 2016 | Skr6.66 Billion | +170.59% |
| 2015 | Skr2.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Immunovia publ AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.94 Million USD |
| MoneyControl | $13.94 Million USD |
| MarketWatch | $13.94 Million USD |
| marketcap.company | $13.94 Million USD |
| Reuters | $13.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunovia publ AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.